STOCK TITAN

Oculis Holding AG - OCS STOCK NEWS

Welcome to our dedicated news page for Oculis Holding (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oculis Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oculis Holding's position in the market.

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) provides updates on its late-stage clinical trials and management appointments. The company completed enrollment in the Phase 2b RELIEF trial of OCS-02 for Dry Eye Disease, initiated the DIAMOND-2 Phase 3 trial for Diabetic Macular Edema, and made key executive appointments. Topline results for the RELIEF trial are expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
clinical trial
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced its participation in upcoming investor conferences, including the Stifel Biotech Executive Summit and BioCapital Europe 2024. The company's CEO and CFO will be presenting at these events, providing an opportunity for interested investors to engage with Oculis' management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
conferences
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced an in-person R&D Day in New York City to showcase two clinical programs: OCS-01, a high concentration dexamethasone eye drop formulation for Diabetic Macular Edema, and OCS-02, a TNFα inhibitor licaminlimab eye drop formulation for Dry Eye Disease. The event will feature presentations from renowned medical professionals and provide a 2023 review and business outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
conferences
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced the initiation of the second Phase 3 OPTIMIZE-2 trial with OCS-01, a once-daily eye drop for the treatment of inflammation and pain following cataract surgery. The trial aims to support the NDA submission to the FDA, with the topline readout expected before the end of 2024. OCS-01 is also being evaluated for the treatment of Diabetic Macular Edema (DME) and Cystoid Macular Edema (CME) in separate trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
clinical trial
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announces the initiation of the DIAMOND-1 Phase 3 trial to evaluate the efficacy and safety of OCS-01 eye drops in treating Diabetic Macular Edema (DME) patients. Stage 1 results demonstrated the superiority of OCS-01 over the vehicle, with robust statistical significance and no unexpected adverse events. OCS-01 has the potential to become the first topical eye drop and non-invasive treatment option for DME. The second 52-week Phase 3 trial, DIAMOND-2, is anticipated to start in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
clinical trial
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announces the initiation of the Phase 2b RELIEF trial to evaluate the potential of licaminlimab (also known as OCS-02), a novel anti-TNFα biologic eye drop, for the treatment of Dry Eye Disease (DED). The trial aims to assess the efficacy and safety of licaminlimab in moderate-to-severe DED, with topline results expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
clinical trial
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) reported that its lead product candidate OCS-01 eye drop met primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery, following a positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME). The company also enrolled the first patient in the investigator-initiated LEOPARD trial evaluating OCS-01 for the treatment of cystoid macular edema (CME). Oculis has cash and investments of $116.5 million, which is adequately funded to deliver on key business and clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
earnings
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced that its CEO and CFO will be presenting at upcoming investor conferences, including the Stifel 2023 Healthcare Conference and BTIG 3rd Annual Ophthalmology Day. The management team will also attend the Piper Sandler 35th Annual Healthcare Conference, offering one-on-one meetings for interested investors. Links to access company presentation and webcast for select events will be posted to Oculis’ website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences
-
Rhea-AI Summary
Oculis Holding AG announced positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME). The results will be presented at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting. OCS-01 is the first investigational eye drop for both front and back of the eye indications, with positive results in previous trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
conferences clinical trial
Rhea-AI Summary
Oculis announces positive results from Phase 3 DIAMOND trial for DME
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
clinical trial
Oculis Holding AG

Nasdaq:OCS

OCS Rankings

OCS Stock Data

437.22M
23.91M
8.26%
37.71%
0.06%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Zug